查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595133

膀胱過動症治療市場：依藥物治療、疾病類型、分佈分類 - 全球預測 2025-2030

Overactive Bladder Treatment Market by Drug Therapy (Anticholinergic, BOTO, Darifenacin), Disease Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

膀胱過動症治療市場2023年估值為45.4億美元，預計到2024年將達到47.1億美元，複合年成長率為3.74%，預計到2030年將達到58.8億美元。

膀胱過動症(OAB) 治療市場針對全球個人，重點在於旨在控制尿急、頻尿和尿失禁等症狀的產品和治療解決方案。由於人口老化和膀胱疾病盛行率的增加，需要有效的膀胱過動症治療，並且需要藥物和非藥物治療來改善患者的生活品質。應用範圍從口服藥物和膀胱內治療到先進的神經調節劑和行為干涉，最終用戶包括醫院、泌尿系統診所和居家醫療機構。市場成長受到藥物配方進步、醫療保健支出增加以及意識和診斷率提高等因素的影響。藥物和醫療設備的技術進步提供了寶貴的機會，特別是在開發靶向生技藥品和微創治療方面，而製藥公司和研究機構之間的合作不斷加強，有助於培育創新解決方案。挑戰包括新治療方法的高成本、監管障礙以及發展中地區的意識低下，這些都可能限制成長潛力。現有治療方法的安全問題和副作用使患者的依從性和採用更加複雜。策略建議包括投資研究和開發，以提高現有治療方法的有效性並減少副作用。鼓勵公司專注於以患者為中心的創新和數位化，以最佳化治療計劃。例子包括部署人工智慧和機器學習來進行病患監測和個人化治療調整。創新還可以集中於將生活方式介入與藥物治療相結合的組合方法，以實現全人管理。隨著需求的成長，透過策略夥伴關係和高效的供應鏈框架，新興市場存在著巨大的擴張空間。 OAB 治療市場仍然充滿活力，一直朝著創新、經濟高效且易於使用的解決方案發展，這對於維持成長和加強患者照護至關重要。

主要市場統計
基準年[2023] 45.4億美元
預測年份 [2024] 47.1億美元
預測年份 [2030] 58.8億美元
複合年成長率（%） 3.74%

市場動態：揭示快速發展的膀胱過動症治療市場的關鍵市場洞察

膀胱過動症治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 患有膀胱過動症(OAB) 症狀的人數增加
    • 人口老化加劇
  • 市場限制因素
    • 膀胱過動症治療相關的副作用和風險
  • 市場機會
    • 膀胱過動症臨床研究試驗和管道
  • 市場挑戰
    • 對膀胱過動症認知不足

波特五力：駕馭膀胱過動症治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解膀胱過動症治療市場的外在影響

外部宏觀環境因素在塑造膀胱過動症治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解膀胱過動症治療市場的競爭格局

膀胱過動症治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣膀胱過動症治療市場供應商的績效評估

FPNV定位矩陣是評估膀胱過動症治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了膀胱過動症治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對膀胱過動症治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 患有膀胱過動症(OAB) 症狀的人數不斷增加
      • 人口老化加劇
    • 抑制因素
      • 膀胱過動症治療相關的副作用和風險
    • 機會
      • 膀胱過動症臨床研究試驗和管道
    • 任務
      • 對 OAB 狀況認知的局限性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章藥物治療膀胱過動症症市場

  • 抗膽鹼能藥
  • 波托
  • 達非那新
  • 非索羅定
  • Mirabegron
  • 神經刺激
  • 奧昔布寧
  • 索利那新

第7章膀胱過動症治療市場：依疾病類型

  • 特發性膀胱過動症
  • 神經源性膀胱過動症

第8章膀胱過動症症治療市場經銷商

  • 醫院和醫院藥房
  • 網路藥房
  • 零售藥房

第9章北美和南美膀胱過動症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區膀胱過動症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲膀胱過動症治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Allergan plc
  • Astellas Pharma Inc.
  • Cipla Limited
  • DETROL LA by Viatris Company
  • Endo International plc
  • Granules India Limited
  • Hisamitsu Pharmaceutical Co., Inc.
  • Medtronic plc
  • Mylan NV
  • Pfizer Inc.
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Urovant Sciences Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-036C5CF3B4ED

The Overactive Bladder Treatment Market was valued at USD 4.54 billion in 2023, expected to reach USD 4.71 billion in 2024, and is projected to grow at a CAGR of 3.74%, to USD 5.88 billion by 2030.

The overactive bladder (OAB) treatment market focuses on products and therapeutic solutions designed to manage symptoms such as urinary urgency, frequency, and incontinence affecting individuals worldwide. The necessity for effective OAB treatments arises from a growing aging population and increased prevalence of bladder disorders, which necessitates ongoing innovation in pharmacological and non-pharmacological therapies to improve patient quality of life. Applications extend from oral medications and intravesical therapies to advanced neuromodulation devices and behavioral interventions, with end-users encompassing hospitals, urological clinics, and home healthcare settings. Market growth is influenced by factors such as advancements in drug formulations, increasing healthcare expenditure, and heightened awareness and diagnosis rates. Technological advancements in pharmaceuticals and medical devices present valuable opportunities, particularly in the development of targeted biologics and minimally invasive treatments, while increasing collaborations between pharmaceutical companies and research institutions can aid in fostering innovative solutions. Challenges include high costs associated with new treatment modalities, regulatory hurdles, and limited awareness in developing regions, which may constrain growth potential. Safety concerns and side effects of existing treatment options further complicate patient compliance and adoption. Strategic recommendations involve investing in R&D to enhance the efficacy and reduce side effects of existing treatments. Companies are encouraged to focus on patient-centric innovations and digitization to optimize treatment plans; for instance, deploying AI and machine learning for patient monitoring and personalized therapy adjustments. Innovation could also focus on combinatory approaches that integrate lifestyle interventions with pharmacotherapy for holistic management. With growing demand, there is significant room for expansion in emerging markets through strategic partnerships and efficient supply chain frameworks. The OAB treatment market remains dynamic, with a strong trajectory toward innovative, cost-effective, and accessible solutions crucial for sustaining growth and enhancing patient care.

KEY MARKET STATISTICS
Base Year [2023] USD 4.54 billion
Estimated Year [2024] USD 4.71 billion
Forecast Year [2030] USD 5.88 billion
CAGR (%) 3.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Overactive Bladder Treatment Market

The Overactive Bladder Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growth in number of people with overactive bladder (OAB) symptoms
    • Increase in aging population
  • Market Restraints
    • Adverse effects and risk associated with overactive bladder treatment
  • Market Opportunities
    • Overactive bladder clinical research trials and pipeline
  • Market Challenges
    • Limited awareness of OAB condition

Porter's Five Forces: A Strategic Tool for Navigating the Overactive Bladder Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Overactive Bladder Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Overactive Bladder Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Overactive Bladder Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Overactive Bladder Treatment Market

A detailed market share analysis in the Overactive Bladder Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Overactive Bladder Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Overactive Bladder Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Overactive Bladder Treatment Market

A strategic analysis of the Overactive Bladder Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Overactive Bladder Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Astellas Pharma Inc., Cipla Limited, DETROL LA by Viatris Company, Endo International plc, Granules India Limited, Hisamitsu Pharmaceutical Co., Inc., Medtronic plc, Mylan N.V., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Urovant Sciences Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Overactive Bladder Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Therapy, market is studied across Anticholinergic, BOTO, Darifenacin, Fesoterodine, Mirabegron, Neurostimulation, Oxybutynin, and Solifenacin.
  • Based on Disease Type, market is studied across Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity.
  • Based on Distribution, market is studied across Hospital & Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growth in number of people with overactive bladder (OAB) symptoms
      • 5.1.1.2. Increase in aging population
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effects and risk associated with overactive bladder treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Overactive bladder clinical research trials and pipeline
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness of OAB condition
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Overactive Bladder Treatment Market, by Drug Therapy

  • 6.1. Introduction
  • 6.2. Anticholinergic
  • 6.3. BOTO
  • 6.4. Darifenacin
  • 6.5. Fesoterodine
  • 6.6. Mirabegron
  • 6.7. Neurostimulation
  • 6.8. Oxybutynin
  • 6.9. Solifenacin

7. Overactive Bladder Treatment Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Idiopathic Bladder Overactivity
  • 7.3. Neurogenic Bladder Overactivity

8. Overactive Bladder Treatment Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital & Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Overactive Bladder Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Overactive Bladder Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Overactive Bladder Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Astellas Pharma Inc.
  • 4. Cipla Limited
  • 5. DETROL LA by Viatris Company
  • 6. Endo International plc
  • 7. Granules India Limited
  • 8. Hisamitsu Pharmaceutical Co., Inc.
  • 9. Medtronic plc
  • 10. Mylan N.V.
  • 11. Pfizer Inc.
  • 12. Sunovion Pharmaceuticals Inc.
  • 13. Teva Pharmaceutical Industries Ltd.
  • 14. Urovant Sciences Inc.
  • 15. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. OVERACTIVE BLADDER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OVERACTIVE BLADDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OVERACTIVE BLADDER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OVERACTIVE BLADDER TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DARIFENACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY FESOTERODINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY MIRABEGRON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY OXYBUTYNIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SOLIFENACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY IDIOPATHIC BLADDER OVERACTIVITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROGENIC BLADDER OVERACTIVITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY HOSPITAL & HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 150. OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. OVERACTIVE BLADDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023